Imagine discovering a treatment that fights aggressive prostate cancer just as effectively in your 80s as it does in your 50s—that's the game-changing insight from the latest TRITON3 trial updates. If you're dealing with or researching metastatic castration-resistant prostate cancer (mCRPC), especially when it's linked to BRCA gene mutations, this could reshape how we approach care for patients of all ages.
Rucaparib, marketed as Rubraca, has proven itself as a reliable warrior in the battle against BRCA-mutated mCRPC, offering steady improvements in radiographic progression-free survival (rPFS)—that's the time before the cancer shows clear signs of worsening on scans—across every age bracket. This reinforces why it's a go-to option for doctors treating this tough form of prostate cancer, which doesn't respond to standard hormone therapies and has spread to other parts of the body.
Fresh insights from the phase 3 TRITON3 study (NCT02975934), presented at the 26th Annual Meeting of the Society of Urologic Oncology, highlight how rucaparib outperformed the doctor's pick between docetaxel chemotherapy or androgen receptor pathway inhibitors (ARPIs) like abiraterone or enzalutamide. No matter the patient's age, the benefits held strong. In the full group of BRCA-mutated patients, those on rucaparib (201 people) saw a median rPFS of 11.2 months, compared to just 6.4 months for the control group (101 people). That's a hazard ratio (HR) of 0.50, with a 95% confidence interval (CI) of 0.36-0.69, meaning a 50% lower risk of progression on scans.
Let's dive deeper into the age breakdowns to see how this plays out. For folks younger than 65, rucaparib gave a median rPFS of 11.2 months (95% CI, 8.7-14.2) versus 6.3 months (95% CI, 2.3-12.0) with the alternative therapy (HR, 0.60; 95% CI, 0.33-1.08). Patients aged 65 to 74 fared similarly well, with 11.2 months (95% CI, 8.2-16.5) on rucaparib against 7.6 months (95% CI, 5.7-9.0) on the other option (HR, 0.46; 95% CI, 0.28-0.75). And here's something striking for our older warriors: those 75 and up achieved a median rPFS of 11.2 months (95% CI, 8.3-15.0) with rucaparib, beating out 5.4 months (95% CI, 3.7-8.4) in the control arm (HR, 0.41; 95% CI, 0.22-0.74). This amounted to a whopping 59% drop in the risk of radiologic progression—think of it as the cancer being held at bay much longer, giving patients more quality time.
Key Highlights from the TRITON3 Updates on Rucaparib for mCRPC
Across the board, rucaparib boosted rPFS significantly over the physician's choice in BRCA-mutated mCRPC patients, no matter their age group.
The advantages seemed to grow even stronger as patients got older, with those 75+ seeing the biggest relative cut in progression risk at 59%—a reminder that age doesn't have to limit effective treatment.
Rucaparib's side effects stayed manageable overall, with common issues like tiredness and low red blood cell counts (anemia), but nothing drastically worse by age except for slightly higher anemia in seniors. For beginners, this means the drug is generally well-tolerated, allowing most patients to stick with it without major disruptions to daily life.
See AlsoCan SMS Revive Africa’s TB Care? Africa CDC Pilot with $100k World Bank GrantOral Cancer Prevention: Superfoods to Boost Your Immune System and Reduce Risk4 Early Signs of Parkinson's Disease in Young Adults: Neurologist's WarningREMINDER Program: How Neuropsychological Exercises Can Reduce Dementia Risk
As Alan H. Bryce, MD, a medical oncologist and interim president and chief clinical officer at City of Hope Cancer Center in Phoenix, Arizona, and his team noted in their poster presentation, 'These results back rucaparib as a solid choice for BRCA-mutated mCRPC patients, regardless of how old they are.' It's encouraging to see science challenging the idea that older patients can't handle targeted therapies.
But here's where it gets interesting—should we rethink how we view age in cancer care? And this is the part most people miss: while the data shines, does it fully account for other health factors that often come with age, like heart issues or frailty?
How Was the TRITON3 Trial Set Up to Test Rucaparib in mCRPC?
This was an open-label (meaning everyone knew what treatment they were getting), randomized phase 3 trial that brought in patients new to chemotherapy but battling mCRPC with changes in BRCA1, BRCA2, or ATM genes. These folks had already tried a second-generation ARPI in some earlier stage of their disease. They were split 2:1—two-thirds got 600 mg of rucaparib twice a day (270 patients), while one-third got the doctor's choice: either docetaxel (75 patients) or another round of ARPI like Zytiga (abiraterone acetate) or Xtandi (enzalutamide) (60 patients).
To keep things fair, patients were grouped by their overall health (ECOG performance status of 0, meaning fully active, versus 1, somewhat limited), whether they had liver spread (yes or no), and their specific gene mutation (BRCA1, BRCA2, or ATM). Treatment went on until the cancer progressed on scans; then, it could stop, switch to rucaparib if the doctor thought it wise, or continue past progression if the patient agreed.
The main goal was rPFS, checked by independent experts who didn't know which treatment patients were on (blinded independent central review, or BICR). Other big measures included overall survival (OS, how long patients lived) and objective response rate (ORR, how much tumors shrank).
Early results at around 62 months follow-up showed rucaparib extending scan-based PFS to a median of 10.2 months (95% CI, 8.3-11.2) in the full group, versus 6.4 months (95% CI, 5.6-8.2) for the control (HR, 0.61; 95% CI, 0.47-0.80; P < .001). For those with ATM mutations, it was 8.1 months versus 6.8 months (HR, 0.95; 95% CI, 0.59-1.52)—less dramatic, but still informative. In the BRCA subgroup, OS reached 24.3 months (95% CI, 19.9-25.7) with rucaparib compared to 20.8 months (95% CI, 16.3-23.1) with the alternative (HR, 0.81; 95% CI, 0.58-1.12; P = .21), showing a trend toward longer life.
Back in May 2020, the FDA gave rucaparib accelerated approval for BRCA-mutated mCRPC patients who'd had ARPI and taxane chemo before, based on the phase 2 TRITON2 trial (NCT02952534). There, it scored a confirmed ORR of 44% (95% CI, 31%-57%), with response lasting at least 6.4 months and ongoing for many. The latest analysis zoomed in on age's role in outcomes, sparking this age-stratified look.
A Peek at Patient Backgrounds and Starting Health by Age
For the under-65 crowd (97 total), the average age was 59 (45-64 range) in the rucaparib group (97 patients) and 61 (47-64) in the control (29 patients). Over half were White (59% vs 62%). Half had top-notch health (ECOG 0: 50% vs 55%), the rest mildly limited (ECOG 1: 50% vs 45%). Metastases were common: bone in 87% (rucaparib) vs 93% (control), nodes in 44% vs 35%, and organs in 31% vs 28%. Prior treatments included abiraterone in 57% vs 59%, enzalutamide in 47% vs 45%, and docetaxel for earlier hormone-sensitive prostate cancer in 38% vs 38%. Most (84% vs 69%) had at least one prior CRPC therapy.
In the 65-74 group (117 patients), median age was 70 (65-74) for rucaparib (76 patients) vs 69 (65-74) for control (41). Whites dominated (80% vs 88%). Health: 46% vs 63% ECOG 0, 54% vs 37% ECOG 1. Mets: bone 88% vs 78%, nodes 46% vs 44%, visceral 28% vs 27%. Priors: abiraterone 57% vs 63%, enzalutamide 41% vs 44%, docetaxel 25% vs 12%. Over 80% (82% vs 88%) had prior CRPC treatment.
For 75+ (88 patients), median age 79 (75-90) in rucaparib (57) vs 78 (75-92) in control (31). Whites: 79% vs 87%, with more having ECOG 1 (51% vs 74%). Mets: bone 83% vs 84%, nodes 44% vs 58%, visceral 33% vs 52%. Priors: abiraterone 53% vs 61%, enzalutamide 44% vs 45%, docetaxel 11% vs 10%. About 75% vs 71% had prior CRPC therapy. These details help explain why the trial mirrors real-world diversity.
How Did Rucaparib's Side Effects Look in This Group?
Common side effects in the rucaparib arm included weakness or fatigue (55%-67%), anemia or low hemoglobin (31%-65%), nausea (49%-55%), less hunger (32%-53%), and loose stools (21%-38%). For newcomers to oncology, these are typical for targeted drugs like PARP inhibitors (rucaparib blocks enzymes cancer cells need to repair DNA, exploiting their BRCA weakness).
The researchers noted anemia crept up with age in both arms, and appetite loss worsened in older rucaparib patients. No big spikes in other side effects by age, though severe fatigue and anemia peaked in the 75+ rucaparib group. Overall, it's a profile that supports broad use, but monitoring blood counts is key for seniors.
And this is the part most people miss: while the efficacy is clear, could the higher anemia in older patients signal a need for more tailored supportive care, like blood transfusions or dose tweaks? It's a subtle counterpoint that might make some clinicians hesitate—do the benefits always outweigh these manageable risks in frail elders?
References
Bryce AH, Piulats JP, Ryan CJ, et al. Efficacy of rucaparib vs physician’s choice in patients with BRCA-mutated metastatic castration-resistant prostate cancer by age: Results from the TRITON3 study. Presented at: Society of Urologic Oncology Annual Meeting; December 2-5, 2025; Phoenix, Arizona. Poster #176.
Fizazi K, Piulats JM, Reaume MN, et al. Rucaparib or physician’s choice in metastatic prostate cancer. N Engl J Med. 2023;388(8):719-732. doi:10.1056/NEJMoa2214676
FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. FDA. May 15, 2020. Accessed December 5, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate
Newsletter
Stay up to date on the most recent and practice-changing oncology data
What do you think—does this data convince you that age shouldn't factor into choosing rucaparib for BRCA-mutated mCRPC, or are there scenarios where we'd still prioritize gentler options for older patients? Drop your agreement, disagreement, or questions in the comments; let's spark a discussion!
